Search results
Showing 1 to 15 of 16 results for omalizumab
Omalizumab for previously treated chronic spontaneous urticaria (TA339)
Evidence-based recommendations on omalizumab (Xolair) for treating severe chronic spontaneous urticaria in people of 12 and over.
Omalizumab for treating severe persistent allergic asthma (TA278)
Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.
Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA678)
NICE is unable to make a recommendation on omalizumab (Xolair) for treating chronic rhinosinusitis with nasal polyps in adults because Novartis Pharmaceuticals did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA678
Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults.
Evidence-based recommendations on tezepelumab (Tezspire) for treating severe asthma in people 12 years and over.
In development [GID-TA11355] Expected publication date: 09 July 2024
The Airsonett temperature-controlled laminar airflow device for persistent allergic asthma (MIB8)
NICE has developed a Medtech Innovation Briefing (MIB) on the Airsonett temperature-controlled laminar airflow device for persistent allergic asthma
Alair bronchial thermoplasty system for adults with severe difficult to control asthma (MIB71)
NICE has developed a medtech innovation briefing (MIB) on the Alair bronchial thermoplasty system for adults with severe, difficult to control asthma
Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in adults.
TA ID Appraisal Short title TA201 Asthma (in children) - omalizumab TA265 Bone metastases from solid tumours - denosumab TA566
Dupilumab for treating severe asthma with type 2 inflammation (TA751)
Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.
This guidance has been replaced by NICE technology appraisal guidance 278.
Benralizumab for treating severe eosinophilic asthma (TA565)
Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.
Omalizumab for the treatment of severe persistent allergic asthma in children aged 6–11 (TA201)
This guidance has been updated and replaced by NICE technology appraisal guidance 278.